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Abstract
Background: Obesity is associated with vascular inflammation, fibrosis and reduced high-density lipoproteins
(HDL)-cholesterol. We aimed to investigate whether adenoviral gene transfer with human apolipoprotein (apo)
A-I (Ad.A-I), the main apo of HDL, could exert immunomodulatory effects and counteract vascular inflammation
and fibrosis in ob/ob mice.
Methods: Ad.A-I transfer was performed in 8 weeks (w) old ob/ob mice, which were sacrificed 7 w later. The aorta
was excised for mRNA analysis and the spleen for splenocyte isolation for subsequent flow cytometry and co-culture
with murine fibroblasts. HDL was added to mononuclear cells (MNC) and fibroblasts to assess their impact on adhesion
capacity and collagen deposition, respectively.
Results: Ad.A-I led to a 1.8-fold (p < 0.05) increase in HDL-cholesterol versus control ob/ob mice at the day of sacrifice,
which was paralleled by a decrease in aortic TNF-α and VCAM-1 mRNA expression. Pre-culture of MNC with HDL
decreased their adhesion to TNF-α-activated HAEC. Ad.A-I exerted immunomodulatory effects as evidenced by a
downregulation of aortic NOD2 and NLRP3 mRNA expression and by a 12 %, 6.9 %, and 15 % decrease of the
induced proliferation/activity of total splenic MNC, CD4+, and CD8+ cells in ob/ob Ad.A-I versus control ob/ob
mice, respectively (p < 0.05). Ad.A-I further reduced aortic collagen I and III mRNA expression by 62 % and 66 %,
respectively (p < 0.0005), and abrogated the potential of ob/ob splenocytes to induce the collagen content in
murine fibroblasts upon co-culture. Finally, HDL decreased the TGF-ß1-induced collagen deposition of murine
fibroblasts in vitro.
Conclusions: Apo A-I transfer counteracts vascular inflammation and fibrosis in ob/ob mice.
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Background
Obesity is an inflammatory disorder [1] associated with
endothelial dysfunction [2], vascular fibrosis [3], and an
increased cardiovascular risk [4, 5]. It is characterized by a
chronic low-grade activation of the innate immune system
[1]. This involves among others the NOD-like receptor
(NLR) family of pattern recognition receptors, includ-
ing the NLRP3 inflammasome [6, 7], which senses
obesity-induced stress signals like cholesterol crystals
[6], and NOD2 [8]. Both NLRP3 and NOD2 are
expressed on endothelial cells, stimulate endothelial
inflammation [8–10], and are involved in the patho-
genesis of fibrosis [11, 12]. Inflammation is a well-
established trigger of fibrosis [13]: it can “classically”
induce the activation/proliferation and transdifferen-
tiation of resident fibroblasts to myofibroblasts and
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induce endothelial-to-mesenchymal-transition (EndMT)
[14], a process by which endothelial cells transdifferentiate
into mesenchymal-like cells, characterized by induced α-
smooth muscle actin expression, loss of endothelial cell
markers, and increased collagen deposition [15–17].
Obesity is associated with low high-density lipoprotein
(HDL) cholesterol levels, by which the body weight
inversely correlates with HDL cholesterol [18]. HDL
cholesterol levels are also decreased in several other
inflammatory disorders including atherosclerosis [19],
systemic lupus erythematosus [20], and rheumatoid arth-
ritis [21], suggesting a link between HDL and the im-
mune response. Apolipoprotein A-I (apo A-I) is the
principal apolipoprotein of HDL and plasma levels of
this apolipoprotein strongly correlate with HDL choles-
terol levels. At the molecular and cellular level, HDL/
apo A-I are known to reduce Toll like receptor 4 expres-
sion [22], inhibit antigen presentation [23], and reduce T
cell proliferation [24]. Besides these immunomodulatory
characteristics, HDL/apo A-I are particularly known for
their endothelial-protective properties including their
capacity to facilitate vascular relaxation via activation of
eNOS [25], to restore impaired NO bioavailability [26],
and to decrease the expression of vascular adhesion mol-
ecules [27]. Besides these well-established endothelial-
protective effects, there is accumulating evidence that
HDL and apo A-I also have anti-fibrotic properties: over-
expression of apo A-I in the lung abrogates fibrosis in
experimental silicosis [28], low apo A-I levels predict liver
fibrosis in hepatitis C patients [29], and HDL inversely
correlate to the serum marker of cardiac fibrosis, pro-
collagen type III aminopeptide [30]. Furthermore, we
demonstrated that human apo A-I gene transfer de-
creased cardiac fibrosis in an experimental rat model of
diabetic cardiomyopathy [27]. With respect to the
aorta, it has been shown that infusions of apo A-I mimetic
peptide reduce fibrosis in the aortic root in a mouse
model of aortic valve stenosis [31]. Recently, we showed
that HDL supplementation to human aortic endothelial
cells (HAEC) decreased transforming growth factor
(TGF)-ß1-induced EndMT [14].
Given the endothelial-protective, anti-fibrotic, and
immunomodulatory effects of HDL/apo A-I on the one
hand, and the occurrence of vascular inflammation and
fibrosis, and innate immune activation under obese
conditions on the other hand, we aimed to investigate
whether human apo A-I gene transfer can decrease aor-
tic inflammation and fibrosis in leptin-deficient ob/ob
mice, which are overweight [32], insulin-resistant [33],
and develop vascular inflammation and fibrosis [34, 35].
We next aimed to understand whether apo A-I/HDL
might also affect vascular inflammation and fibrosis via
systemic immunomodulation. In this respect, in vitro
studies were conducted to get insights in whether (i) HDL
modulate the binding capacity of MNC to TNF-α-
activated HAEC; and whether (ii) modulation of splenic
activity following apo A-I transfer influences collagen
production upon co-culture of those splenocytes with
fibroblasts.
Methods
Animals and study design
Male B6.V-Lepod/JRj mice (ob/ob; Janvier Labs, Le Genest-
Saint-Isle, France) were intravenously injected via the tail
vein with saline or with 5 x 1010 total particles of the
E1E3E4-deleted adenoviral vector Ad.A-I expressing
human apo A-I [36] or of Ad.Null containing no ex-
pression cassette [36], at the age of 8 weeks. As control
reference, age-matched male C57BL/6 mice were injected
with saline. Mice were sacrificed 7 weeks later, the aorta
was excised and snap-frozen in liquid nitrogen for
molecular biology and the spleen was isolated for sple-
nocyte preparation and subsequent flow cytometry or
co-culture with murine fibroblasts. Blood was with-
drawn from the retro-orbital plexus at day 7, 21, 35,
and 49 after gene transfer for determination of human
apo A-I concentrations. At day 45 after gene transfer or
saline injection, an intraperitoneal glucose tolerance
test was performed. The investigation conforms with
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996) and was approved
by the Institutional Animal Care and Research Advisory
Committee of the Catholic University of Leuven (Approval
number: P154/2013).
Human apo A-I ELISA
Human apo A-I levels were determined by sandwich
ELISA as described previously [37].
Plasma lipid analysis
Mouse lipoproteins were separated by density gradient
ultracentrifugation as described by Jacobs et al. [38]. Frac-
tions were stored at −20 °C until analysis. Cholesterol in
lipoprotein fractions was determined with commercially
available enzymes (Roche Diagnostics, Basel, Switzerland).
Precipath L (Roche Diagnostics) was used as a standard.
Glucose tolerance test
Glucose tolerance test was performed by intraperitoneal
injection of glucose (2 g/kg) after 6 h (h) of fasting as de-
scribed by Hofmann et al. [39]. Tail blood glucose levels
were measured with an Accu-Chek® Active Glucometer
(Roche Applied Science, Penzberg, Germany) before
(0 min) and at 15, 30, 60 and 120 min after injection.
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Splenocyte isolation
Splenocytes were isolated from the different experimen-
tal groups as described previously [40].
(Splenocyte) mononuclear cell, CD4-, and CD8-T cell
proliferation
Splenocytes were labeled with 10 μM of succinimidyl
ester of carboxyfluorescein diacetate (CFSE Cell Tract™;
Invitrogen, Carlbard, CA, USA) to be able to measure
cell proliferation, indicative for MNC activation, as
described previously [41]. Therefore, splenocytes were
cultured in RPMI1640 medium (Invitrogen, Heidelberg,
Germany), supplemented with 10 % FBS and 1 % peni-
cillin/streptomycin for 72 h. Then, cells were stained
with monoclonal anti-CD4 or anti-CD8 antibodies (BD
Biosciences, Franklin Lakes, NJ, USA), followed by flow
cytometry on a MACSQuant Analyzer (Miltenyi Biotec,
Bergisch Gladbach, Germany) and analysis with FlowJo
8.7. software (Tree Star) for the calculation of the div-
ision index, i.e. the average number of cell divisions that
the responding cells undergo (i.e., ignores peak 0).
TGF-ß1 expressing mononuclear cells
For the analysis of MNC expressing TGF-ß1, spleno-
cytes were intracellulary stained with anti-TGF-ß1
(clone TW7-16B4 recognizing latency associated pep-
tide (LAP), latent TGF-ß, and pro-TGF-ß; Biolegend,
San Diego, CA, USA) after fixation. Splenocyte samples
were acquired on a MACSQuant Analyzer (Miltenyi
Biotec, Bergisch Gladbach, Germany). Analysis of flow
cytometry data was performed using FlowJo software
version 8.8.6. (Tree Star Inc.).
Cell culture
Murine C4 fibroblasts, a murine fibroblast cell line derived
from embryonic BALB/c mice by SV40 infection in vitro
[42], were cultured in Basal Iscove medium supplemented
with 10 % FBS and 1 % Penicillin/Streptomycin. Twenty-
four h after plating at a cell density of 10,000 cells/96-well,
cells were stimulated with/out 10 ng/ml TGF-ß1 (R&D
Systems, Minneapolis, USA) under serum starvation
conditions, i.e. Basal Iscove medium with 0.01 % FBS and
1 % Pencillin/Streptomycin, in the presence or absence of
50 μg/ml of HDL (MP Biomedicals, Solon, Ohio, USA)
for 24 h. Next, cells were fixed in methanol overnight
at −20 °C for subsequent collagen deposition staining.
Human aortic endothelial cells (HAEC; Lonza, Basel,
Switzerland) were cultured in Endothelial Basal Medium
(Lonza) supplemented with the EGM-2 BulletKit (Lonza)
on pre-coated (coating solution containing 0.02 % gel-
atin from bovine skin type B and 125 ng/ml fibronectin
from bovine plasma; both Merck Chemicals, Darmstadt;
Germany) cell culture flasks.
Co-culture of fibroblasts with splenocytes
Murine C4 fibroblasts were plated at a cell density of
10,000 cells/96-well in Basal Iscove medium supple-
mented with 10 % FBS and 1 % Penicillin/Streptomycin.
Twenty-four h after plating, medium was removed and
splenocytes isolated from control, ob/ob, ob/ob Ad.Null,
and ob/ob Ad.A-I mice were added to the fibroblasts at a
ratio of 10 splenic cells to 1 fibroblast in RPMI1640
medium (Invitrogen, Heidelberg, Germany) 10 % FBS, 1 %
Penicillin/Streptomycin. After 24 h, splenocytes were re-
moved and the murine fibroblasts were fixed in methanol
overnight at −20 °C for subsequent collagen deposition
staining.
Quantification of collagen deposition
Collagen deposition was determined as described previ-
ously [14, 43]. In brief, after overnight fixation in metha-
nol at −20 °C, cells were washed once with PBS and
incubated in 0.1 % Direct Red 80 (Sirius red; Merck
Chemicals, Darmstadt; Germany) staining solution at RT
for 60 min. After second washing with PBS, the Sirius
red staining of the murine fibroblasts was eluted in
0.1 N sodium hydroxide at RT for 60 min on a rocking
platform. The optical density, representative for the
accumulation of collagen, was measured at 540 nm. For
normalization to cell amount, murine fibroblasts were
stained with crystal violet (Merck Chemicals, Darmstadt,
Germany) and the absorbance was measured at 495 nm.
Data are represented as the ratio of the absorbance at
540 nm (Sirius Red) towards the absorbance at 495 nm
(crystal violet).
Human peripheral blood mononuclear cell isolation
Blood was withdrawn from healthy donors (aged 40 to 65)
with approval (EA4/115/11) from the Ethical Commission
(Charité, CBF, Berlin). Human peripheral blood mono-
nuclear cells (MNC) were isolated from the blood sam-
ples by density-gradient centrifugation (Biocoll; Merck
Millipore, Darmstadt, Germany). Cells were stored in
liquid nitrogen until use.
Adhesion assay
HAEC were plated in gelatin/fibronectin-coated black
solid bottom 96-well plates, cultured for 24 h and
treated with 10 ng/ml TNF-α (BD Pharmingen, Franklin
Lakes, NJ, USA) in Endothelial Basal Medium for 4 h
prior to addition of MNC. DiO-labeled human MNC
(DiO, Molecular Probes, Life Technologies) were cul-
tured with/out 50 μg/ml of HDL for 24 h in 24-well
plates and next added to TNF-α-stimulated HAEC at a
ratio of 1:10 for 30 min. Subsequently, MNC were re-
moved by aspiration and HAEC were washed once with
PBS. PBS was added to each well and DiO-fluorescence
was detected with a Mithras LB 940 multitechnology
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microplate reader (Berthold technologies) at wave-
lengths of 485 nm for excitation and 535 nm for emis-
sion and corresponding software (MikroWin 2000,
Mikrotek Laborsysteme GmbH).
Gene expression analysis
RNA from the aorta was isolated using the RNeasy Mini
Kit according to the manufacturer’s protocol (Qiagen
GmbH, Hilden, Germany), followed by cDNA synthesis.
To assess the mRNA expression of the target genes TNF-
α, VCAM-1, CD4, CD8, NOD2, NLRP3, collagen I and
III, real-time PCR (Eppendorf Mastercycler epgradient
realplex, Hamburg, Germany) was performed using gene
expression assays for TNF-α Mm00443258_m1, VCAM-1
Mm01320970_m1, CD4 Mm00442754_m1, and CD8a
Mm01182107_g1, nucleotide-binding oligomerization do-
main containing (NOD) 2 Mm00467543_m1, nucleotide-
binding domain, leucine-rich-containing family, pyrin
domain-containing (NLRP) 3 Mm00840904_m1, Col1a1
Hs00164004_m1, and Col3a1 Hs00943809_m1 from
Applied Biosystems, respectively. mRNA expression was
normalized to the housekeeping gene CDKN1b (gene ex-
pression assay Hs00153277_m1) and relatively expressed
with the control group set as 1.
Statistical analysis
Data are presented as mean ± SEM. Statistical differences
between groups were assessed with Ordinary One-way
ANOVA. Differences were considered to be significant
when the P-value was lower than 0.05.
Results
Metabolic modulation after human apo A-I transfer in ob/
ob mice
Human apo A-I gene transfer resulted in persistent
expression of human apo A-I in ob/ob mice (Fig. 1)
leading to a 79 % (p < 0.001) and 68 % (p < 0.001) in-
crease in HDL cholesterol levels at the day of sacrifice
compared to ob/ob and ob/ob Ad.Null mice, respectively
(Table 1). At this age, ob/ob mice were still normogly-
cemic (Additional file 1: Figure S1A), but already glucose
intolerant as evidenced by an intraperitoneal glucose
tolerance test (Additional file 1: Figure S1B). Ad.A-I
transfer did not improve glucose intolerance (Additional
file 1: Figure S1B).
Human apo A-I transfer exerts anti-inflammatory and im-
munomodulatory effects in ob/ob mice
Given the occurrence of inflammation in the vascula-
ture under obesity on the one hand [1] and the anti-
inflammatory properties of HDL/apo A-I on the other
hand [27, 44], we first evaluated whether apo A-I gene
transfer could reduce aortic inflammation in obese mice.
Apo A-I gene transfer decreased aortic inflammation
present in ob/ob mice as indicated by a 34 % (p < 0.05)
and 34 % (p < 0.01) decrease in aortic TNF-α and VCAM-
1 mRNA expression versus ob/ob mice, respectively
(Fig. 2a-b), and a 65 % (p = 0.066) and 62 % (p = 0.076)
decline in CD4 and CD8 mRNA expression versus ob/ob
mice, respectively (CD4 mRNA C57BL/6: 1 ± 0.28, ob/ob:
1.9 ± 0.44, ob/ob Ad.Null: 2.2 ± 0.69, ob/ob Ad.A-I: 0.66 ±
0.14; CD8 mRNA C57BL/6: 1.0 ± 0.32, ob/ob: 2.9 ± 0.94,
ob/ob Ad.Null: 3.3 ± 1.0, ob/ob Ad.A-I: 1.1 ± 0.19; with
p < 0.05 for ob/ob Ad.A-I versus ob/ob Ad.Null). Fur-
ther evaluation of the pattern recognition receptor
NOD2, which can be induced by TNF-α [9], and of the
pattern recognition receptor NLRP3, demonstrated a
47 % (p < 0.0005) and 52 % (p < 0.05) decline, respect-
ively, in their mRNA expression in ob/ob Ad.A-I versus
ob/ob mice (Fig. 2c-d). To evaluate whether these
changes in vascular inflammation and innate immunity
following apo A-I gene transfer in ob/ob mice were
accompanied with systemic immunomodulation, the
impact of Ad.A-I on the activation/proliferation state of
MNC, CD4+, and CD8+ T cells and on splenic TGF-
ß1-expressing MNC was determined. Ob/ob mice ex-
hibited activated splenic MNC, CD4+, and CD8+ T
cells as shown by a 13 % (p < 0.05), 18 % (p < 0.005),
and 18 % (p < 0.005) higher proliferation capacity
compared to respective splenic cells from control
C57BL/6 mice (Fig. 3a-c). In contrast, apo A-I gene
transfer decreased the activation/proliferation of splenic
total MNC, CD4+, and CD8+ cells in ob/ob mice by 12 %
(p < 0.05), 6.9 % (p < 0.05), and 15 % (p < 0.001), respect-
ively (Fig. 3a-c), and reduced the percentage of MNC
Fig. 1 Human apo A-I levels after apo A-I gene transfer in ob/ob mice.
Data represent mean ± SEM of n = 4 mice
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Table 1 Plasma cholesterol, non-HDL cholesterol, HDL cholesterol and plasma triglycerides at 6 weeks after saline injection or gene
transfer
Cholesterol Non-HDL Cholesterol HDL Cholesterol Triglycerides
C57BL/6 66.7 ± 7.3 15.4 ± 2.0 51.3 ± 5.9 45.6 ± 4.4
Ob/ob 144 ± 7§§§ 71.8 ± 3.9§§§ 72.7 ± 4.3§ 51.6 ± 3.9
Ob/ob Ad.Null 153 ± 2§§§ 76.0 ± 2.5§§§ 77.5 ± 2.7§§ 61.3 ± 5.1
Ob/ob Ad.A-I 218 ± 8§§§$$$*** 87.1 ± 4.3§§§$ 130 ± 5§§§$$$*** 96.3 ± 11.2§§§$$$**
All data are expressed in mg/dl and represent means + SEM (n = 7 for C57BL/6, n = 11 for ob/ob, n = 12 for ob/ob Ad.Null, n = 12 for ob/ob Ad.A-I). §: p < 0.05; §§: p
< 0.01; §§§: p < 0.001 versus C57BL/6. $: p < 0.05; $$$: p < 0.001 versus ob/ob. **: p < 0.01; ***: p < 0.001 versus ob/ob Ad.Null
Fig. 2 Impact of apo A-I gene transfer on aortic TNF-α, VCAM-1, NOD2, and NLRP3 mRNA expression in ob/ob mice. Bar graphs represent the
mean ± SEM of aortic a. TNF-α, b. VCAM-1, c. NOD2 and d. NLRP3 mRNA expression with n = 6-7 for C57BL/6, n = 11 for ob/ob, n = 8–10 for ob/ob Null
and n = 10 for ob/ob A-I; *p < 0.05, **p < 0.01, ***p < 0.005 and ****p < 0.0001
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Fig. 3 (See legend on next page.)
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expressing TGF-ß1 by 28 % (p < 0.05) in ob/ob mice
(Fig. 4). To further evaluate whether the immunomodula-
tory effects of HDL also include their ability to reduce
the capacity of MNC to bind to endothelial cells, MNC
pre-cultured with/out HDL were added to TNF-α-
stimulated HAEC and their adhesion was measured.
Pre-culture of MNC with HDL resulted in a 63 % (p <
0.0001) lower adhesion to TNF-α-stimulated HAEC
compared to untreated MNC (Fig. 5).
Anti-fibrotic effects after human apo A-I transfer in ob/ob
mice
The relevance of vascular fibrosis in obesity [3] and the
anti-fibrotic effects of HDL/apo A-I [14, 27–31] further
motivated us to evaluate the impact of Ad.A-I on the
aortic mRNA expression of fibrosis markers. Ob/ob
mice exhibited a 459 % (p < 0.0001) and 243 % (p <
0.0005) higher collagen I and III mRNA expression,
respectively, compared to control C57BL/6 mice,
whereas AdA-I transfer in ob/ob mice resulted in a
62 % (p < 0.0005) decrease of collagen I mRNA and a
66 % (p < 0.0005) decrease of collagen III mRNA
(Fig. 6). Given the link between immune cells and fibro-
sis on the one hand [13] and the importance of fibrosis
in vascular remodeling on the other hand [45], we next
evaluated the impact of the immunomodulatory effects
of apo A-I gene transfer on collagen production in fi-
broblasts upon co-culture of splenocytes isolated from
the different experimental groups on fibroblasts. Co-
culture of splenocytes from ob/ob and ob/ob Ad.Null
mice with murine fibroblasts augmented collagen de-
position by 54 % (p < 0.0001) and 50 % (p < 0.0005), re-
spectively, compared to monoculture of fibroblasts. In
contrast, splenocytes from ob/ob Ad.A-I mice and from
control mice did not induce collagen content in fibro-
blasts upon co-culture (Fig. 7a). To evaluate whether
HDL themselves reduce collagen deposition in murine
fibroblasts, HDL were supplemented to fibroblasts
stimulated with TGF-ß1. TGF-ß1 increased the collagen
deposition in murine fibroblasts by 43 % (p < 0.01). In
contrast, HDL reduced the TGF-ß1-induced collagen de-
position to levels not different from controls (Fig. 7b).
Discussion
The salient findings of the present study are that apo
A-I gene transfer exerts immunomodulatory effects and
Fig. 4 Impact of apo A-I gene transfer on splenic TGF-ß +mononuclear
cells. Bar graphs represent the mean ± SEM of the % of splenic TGF-ß +
mononuclear cells (MNC) with n = 5-6/group; *p < 0.05
Fig. 5 Supplementation of high-density lipoproteins on human
mononuclear cells reduces their subsequent adhesion to human
aortic endothelial cells. Bar graphs represent the mean ± SEM of the
absorbance at 535 nm with n = 12/group for the untreated MNC
groups and n = 9/group for the HDL-treated MNC groups; *p < 0.05,
**p < 0.005, and ****p < 0.0001
(See figure on previous page.)
Fig. 3 Impact of apo A-I gene transfer on the activity of splenic mononuclear cells, CD4+ and CD8+ T cells in ob/ob mice. Upper
panels: representative peaks, indicative for the amount of cell divisions of splenic a. mononuclear cells (MNC), b. CD4+ and c. CD8+ T
cells from C57BL/6, ob/ob, ob/ob Ad.Null, and ob/ob Ad.A-I mice, as indicated, are shown. Lower panels: Bar graphs represent the
mean ± SEM of the division index of splenic a. MNC, b. CD4+ and c. CD8+ T cells with n = 5-6/group; *p < 0.05, **p < 0.005
and ***p < 0.001
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decreases vascular inflammation and markers of fibrosis
in ob/ob mice.
Leptin-deficient ob/ob mice are overweight [32], insulin-
resistant [33], and develop type 2 diabetes mellitus over
time due to deficiency of the appetite regulating hormone
leptin, which has immunomodulatory properties [46]. In
agreement with Xu et al. [47], ob/ob mice were still
normoglycemic at an age of 15 weeks. However, a glucose
tolerance test 4 days before sacrifice indicated a disturb-
ance in glucose metabolism, which could not be overcome
via apo A-I gene transfer. Furthermore, ob/ob mice exhib-
ited hypercholesterolemia and dyslipoproteinemia (non-
HDL to HDL-cholesterol ratio 1:1) in the absence of
raised triglyceride levels. In agreement with apo A-I gene
transfer studies in certain atherosclerosis models [48, 49],
Ad.A-I transfer induced increased triglyceride levels in ob/
ob mice. Under these metabolic conditions, we demon-
strate that apo A-I gene transfer led to a downregulation
of aortic TNF-α and VCAM-1 mRNA in ob/ob mice. We
and others have shown that apo A-I reduces TNF-α ex-
pression [27, 50], which is an important inducer of
VCAM-1 expression [44]. Downregulation of aortic
VCAM-1 mRNA expression in ob/ob mice after apo A-I
gene transfer is - on its turn - in agreement with the well-
established potential of apo A-I and HDL to decrease the
expression of cytokine-induced adhesion molecules [44].
This downregulated aortic VCAM-1 together with the
decreased CD4 and CD8a mRNA expression in ob/ob
Fig. 6 Impact of apo A-I gene transfer on aortic collagen I and III mRNA expression in ob/ob mice. Bar graphs represent the mean ± SEM of aortic
a. collagen I and b. collagen III mRNA expression with n = 7 for C57BL/6, n = 9-10 for ob/ob groups; *p < 0.05, **p < 0.0005, and ***p < 0.0001
Fig. 7 High-density lipoproteins reduce collagen deposition in murine fibroblasts via immunomodulatory and direct anti-fibrotic properties. Bar
graphs represent the mean ± SEM of the ratio of the absorbance at 540 nm of Sirius Red-stained murine fibroblasts towards the absorbance at
495 nm of crystal violet-stained murine fibroblasts cultured a) in the absence (basal) or presence of splenocytes isolated from C57BL/6, ob/ob,
ob/ob Ad.Null and ob/ob Ad.A-I mice, as indicated, at a ratio of 10 splenocytes to 1 fibroblast for 24 h, with n = 5-6/group and *p < 0.05, **p < 0.005,
***p < 0.0005, and ****p < 0.0001 and b) depict the mean ± SEM of the ratio of the absorbance at 540 nm of Sirius Red-stained murine fibroblasts
towards the absorbance at 495 nm of crystal violet-stained murine fibroblasts in the presence of TGF-ß1 with/out HDL supplementation for 24 h, with
the different groups as indicated: n = 12/control, HDL, and TGF-ß1 + HDL groups and n = 9/TGF-ß1 group with *p < 0.05, **p < 0.01 and ****p < 0.0001
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Ad.A-I compared to ob/ob mice suggests a lower presence
of CD4 and CD8 cells in the aorta of ob/ob Ad.A-I com-
pared to ob/ob mice. Our in vitro findings further illus-
trate that HDL lower the capacity of MNC to adhere to
TNF-α-activated aortic endothelial cells. This implies that
HDL can decrease the adhesion of immune cells to the
aortic endothelium via their endothelial-protective (lower-
ing VCAM-1 expression) as well as immunomodulating
capacity (decreasing the binding capacity of MNC to
activated endothelial cells). This impaired immune cell
adhesion and consequently lower presence of immune
cells in the vascular wall, were expected to reduce fibrosis
in the aorta of ob/ob Ad.A-I versus ob/ob mice, due to the
lower burden of inflammation [13]. Indeed, we found that
the aortic collagen I and III mRNA expression was lower
in ob/ob Ad.A-I versus ob/ob mice, which can also be ex-
plained via a direct anti-fibrotic effect of HDL. This mech-
anism is corroborated by our in vitro finding indicating
that HDL reduce the TGF-ß1-induced collagen deposition
in murine fibroblasts and is further supported by our
recent observation that HDL are capable of decreasing
TGF-ß1-induced EndMT in aortic endothelial cells in
vitro [14]. In this context, another explanation for the
reduction in aortic collagen expression following apo
A-I gene transfer could be the decrease in TGF-ß1-ex-
pressing splenic MNC in ob/ob Ad.A-I versus ob/ob
mice, and subsequent lower induction of EndMT in ob/
ob mice.
Evidence for the immunomodulatory capacity of apo
A-I gene transfer in ob/ob mice follows at first from the
reduction in aortic mRNA expression of the NLR proteins
NOD2 and NLRP3 in ob/ob Ad.A-I versus ob/ob mice.
NOD2 leads to NF-kB activation and subsequent expres-
sion of TNF-α and NLRP3 [51]. Its downregulation fol-
lowing apo A-I gene transfer can therefore partly
explain the reduction in aortic TNF-α expression.
Based on the involvement of NOD2 in fibrosis [11], its
endothelial expression [9] and the capacity of HDL to
reduce EndMT [14], we further speculate that an increase
of HDL via apo A-I gene transfer can partly account for
the reduction in aortic collagen I and III expression via
decreasing EndMT, involving NOD2. The aortic downreg-
ulation of NLRP3, which has emerged as an important
regulator of inflammation in metabolic disorders and
atherosclerosis [6, 7] and is recognized for its capacity to
induce collagen production in fibroblasts [12], supports
the link between the decrease in vascular inflammation
and fibrosis after apo A-I gene transfer.
Besides its impact on the aortic expression of NLRs,
Ad.A-I transfer led to systemic immunomodulatory ef-
fects as indicated by a decline in the increased prolifer-
ation/activity of splenic MNC, CD4+ and CD8+ T cells
in ob/ob mice. This finding is supported by Wilhelm et
al. [24] who showed that apo A-I prevents T cell
activation and proliferation in peripheral lymph nodes
in mice fed an atherogenic diet. In addition, we found that
apo A-I gene transfer reduced the percentage of splenic
MNC expressing the pro-fibrotic factor TGF-ß1. Con-
comitantly, co-culture of splenocytes from ob/ob Ad.A-I
mice did not induce collagen production in murine fibro-
blasts, in contrast to splenocytes from ob/ob and ob/ob
Ad.Null mice, suggesting that apo A-I-raising transfer re-
duces the pro-fibrotic potential of splenocytes under obese
conditions and their subsequent contribution to vascular
fibrosis. This hypothesis, supporting the existence of a vas-
culosplenic axis, i.e. the migration of immune cells from
the spleen to the vasculature and subsequent involvement
in vascular fibrosis builds further on the existence of the
cardiosplenic axis, which importance has mainly been rec-
ognized in ischemic heart disease [52]. This postulation
should be taken with caution as long as the existence of a
vasculosplenic axis and its relevance in vascular fibrosis is
confirmed in additional experiments in ob/ob mice.
Limitations of the study
Whereas the present study reveals systemic immuno-
modulatory and local (aorta) immunomodulatory/anti-
fibrotic effects following apo A-I transfer in ob/ob
mice, further characterization of the systemic immuno-
modulatory effects mice including cytokine profiles of
circulating immune cells as well as the analysis of fibro-
sis in other vascular beds and/or adipose tissue is re-
quired to deepen our insights into the link between
inflammation and fibrosis in ob/ob mice and the impact
of apo A-I transfer on both parameters. Furthermore,
experiments in high-fat diet-induced obesity, associated
with hyperleptineamia (dysfunctional leptin), would be
of value to confirm our findings.
Conclusions
We demonstrated that apo A-I-raising transfer exerts
immunomodulatory effects in ob/ob mice, including
the reduction in the aortic expression of the pattern
recognition receptors NOD2 and NLRP3, and the de-
crease in activity of splenic MNC, which are associated
with a decrease in vascular inflammation and fibrosis.
These findings further corroborate the immunomodula-
tory and vascular-protective potential of apo A-I/HDL.
Furthermore, they point out that under obese conditions,
modulation of the chronic low-grade activation of the
innate immune system (NOD2, NLRP3) per se, may coun-
teract vascular inflammation and fibrosis.
Additional file
Additional file 1: Figure S1. Impact of apo A-I transfer on blood glu-
cose levels and glucose responsiveness in ob/ob mice. (TIFF 1521 kb)
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